Promega announced that its OncoMate microsatellite instability (MSI) diagnosis system for solid tumors has the CE Mark as a new in vitro diagnostic in Europe.
The polymerase chain reaction-based test is designed to assess MSI status, an increasingly important biomarker in recent years in solid tumors, including colorectal cancer and endometrial cancer. Readings are complementary to standard mismatch repair immunohistochemistry panels and can be used as an independent biomarker to help predict response to immunotherapies, Promega noted in a statement. The company also intends to get the product cleared in the U.S. and China.
